EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Interleukin‐11 expressed in the polyp‐enriched fibroblast subset is a potential therapeutic target in Peutz‐Jeghers syndrome

Eva Domènech-Moreno iD, Wei-Wen Lim iD, Melissa G Montrose, Myriam Sévigny iD, Anders Brandt, Toni T Lemmetyinen iD, Emma W Viitala iD, Tomi P Mäkelä iD, Stuart A Cook, Saara Ollila iD

The Journal of Pathology · 2025

DOI: 10.1002/path.6408 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pathology, 2025. Verfasst von Eva Domènech-Moreno und 9 weiteren Autor:innen. Beteiligte Einrichtung: HiLIFE-Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland. Hauptthemen laut MEDLINE: Peutz-Jeghers Syndrome, Fibroblasts, Interleukin-11, Intestinal Polyps. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Academy of Finland, University of Helsinki Research Foundation, Finnish Cancer Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Peutz‐Jeghers syndrome (PJS) is associated with early‐onset gastrointestinal polyposis caused by hereditary inactivating pathogenic variants in the tumor suppressor gene STK11 ( LKB1 ). Due to lack of prophylactic therapies, management of PJS polyps requires frequent surveillance. Interestingly, studies in mouse models have revealed that stromal cells drive the polyp formation, but detailed understanding of the cell types and interactions involved has been lacking. Using single‐cell RNA sequencing of PJS mouse model polyps, we here identify a polyp‐enriched crypt top fibroblast (pCTF) cluster characterized by a transcriptional signature also enriched in PJS patient polyps. The pCTF signature was also noted in primary fibroblasts in vitro following acute STK11 loss. Targeted deletion of Stk11 in crypt top fibroblasts using Foxl1 ‐ Cre led to upregulation of the pCTF signature genes and later to polyposis. pCTFs displayed similarity to inflammation‐associated fibroblasts, and polyposis was exacerbated by inflammation. Cell–cell communication analysis identified interleukin 11 (IL‐11) as a potential pCTF inducer, and consistent with this, IL‐11 was required for fibroblast reprogramming toward pCTFs following STK11 loss. Importantly, a neutralizing IL‐11 antibody efficiently reduced polyp formation in a PJS model indicating a key, targetable role for IL‐11 in polyp development. Together the results characterize pCTFs as a PJS polyp‐enriched fibroblast subset and identify IL‐11 as a key mediator of fibroblast reprogramming and a potential therapeutic target in PJS. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Peutz-Jeghers SyndromeFibroblastsInterleukin-11Intestinal PolypsAnimalsHumansProtein Serine-Threonine KinasesMiceAMP-Activated Protein Kinase KinasesDisease Models, AnimalMice, KnockoutCells, CulturedSignal TransductionAMP-Activated Protein Kinases

Stichwörter der Autor:innen

LKB1Peutz‐Jeghers syndromeSTK11interleukin‐11polyposissingle‐cell RNA sequencingtherapy

Substanzen

Interleukin-11Protein Serine-Threonine KinasesAMP-Activated Protein Kinase KinasesSTK11 protein, humanStk11 protein, mouseAMP-Activated Protein Kinases

Autor:innen und Institutionen

  • HiLIFE-Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland.
  • iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland.
  • National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore, Singapore.
  • Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School, Singapore, Singapore.
  • Translational Cancer Medicine Program, University of Helsinki, Helsinki, Finland.
  • Faculty of Biological and Environmental Sciences, Molecular and Integrative Biosciences Research Program, University of Helsinki, Helsinki, Finland.

ORCID-Profile: Eva Domènech-Moreno, Wei-Wen Lim, Myriam Sévigny, Toni T Lemmetyinen, Emma W Viitala, Tomi P Mäkelä, Saara Ollila

Förderung

  • Academy of Finland
  • University of Helsinki Research Foundation
  • Finnish Cancer Foundation
  • Biomedicum Helsinki-säätiö
  • K. Albin Johanssons Stiftelse
  • National Medical Research Council
  • Singapore Translational Research Investigator Award
  • Clinician Scientist Individual Research

Zitieren

APA

Domènech-Moreno, E., Lim, W. W., Montrose, M. G., Sévigny, M., Brandt, A., Lemmetyinen, T. T., Viitala, E. W., Mäkelä, T. P., Cook, S. A., & Ollila, S. (2025). Interleukin‐11 expressed in the polyp‐enriched fibroblast subset is a potential therapeutic target in Peutz‐Jeghers syndrome. The Journal of Pathology. https://doi.org/10.1002/path.6408

Vancouver

Domènech-Moreno E, Lim WW, Montrose MG, Sévigny M, Brandt A, Lemmetyinen TT, et al. Interleukin‐11 expressed in the polyp‐enriched fibroblast subset is a potential therapeutic target in Peutz‐Jeghers syndrome. The Journal of Pathology. 2025. doi:10.1002/path.6408

BibTeX
@article{DomnechMoreno2025,
  author = {Domènech-Moreno, Eva and Lim, Wei-Wen and Montrose, Melissa G and Sévigny, Myriam and Brandt, Anders and Lemmetyinen, Toni T and Viitala, Emma W and Mäkelä, Tomi P and Cook, Stuart A and Ollila, Saara},
  title = {Interleukin‐11 expressed in the polyp‐enriched fibroblast subset is a potential therapeutic target in Peutz‐Jeghers syndrome},
  journal = {The Journal of Pathology},
  year = {2025},
  doi = {10.1002/path.6408}
}
Kostenlos starten →